160 related articles for article (PubMed ID: 7558417)
1. Among 17 inducers of differentiation only sodium butyrate causes a permanent down-regulation of c-myc in Burkitt's lymphoma.
Rottleb C; Bornkamm GW; Polack A
Int J Cancer; 1995 Sep; 62(6):697-702. PubMed ID: 7558417
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship of 17 structural analogues of n-butyric acid upon c-myc expression.
Rottleb C; Hall C; Bornkamm GW; Polack A
Int J Cancer; 1996 Sep; 67(5):724-9. PubMed ID: 8782665
[TBL] [Abstract][Full Text] [Related]
3. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
4. Truncation does not abrogate transcriptional downregulation of the c-myc gene by sodium butyrate in Burkitt's lymphoma cells.
Polack A; Eick D; Koch E; Bornkamm GW
EMBO J; 1987 Oct; 6(10):2959-64. PubMed ID: 3691477
[TBL] [Abstract][Full Text] [Related]
5. Regulatory elements in the immunoglobulin kappa locus induce c-myc activation and the promoter shift in Burkitt's lymphoma cells.
Polack A; Feederle R; Klobeck G; Hörtnagel K
EMBO J; 1993 Oct; 12(10):3913-20. PubMed ID: 8404859
[TBL] [Abstract][Full Text] [Related]
6. Transcription-independent repair of nitrogen mustard-induced N-alkylpurines in the c-myc gene in Burkitt's lymphoma CA46 cells.
Wassermann K; O'Connor PM; Jackman J; May A; Bohr VA
Carcinogenesis; 1994 Sep; 15(9):1779-83. PubMed ID: 7923569
[TBL] [Abstract][Full Text] [Related]
7. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
8. Allele-specific activation of the c-myc gene in an atypical Burkitt's lymphoma carrying the t(2;8) chromosomal translocation 250 kb downstream from c-myc.
Tachibana K; Takayama N; Matsuo K; Kato S; Yamamoto K; Ohyama K; Umezawa A; Takano T
Gene; 1993 Feb; 124(2):231-7. PubMed ID: 8444346
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
11. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.
Madisen L; Groudine M
Genes Dev; 1994 Sep; 8(18):2212-26. PubMed ID: 7958890
[TBL] [Abstract][Full Text] [Related]
12. NF-kappa B sites function as positive regulators of expression of the translocated c-myc allele in Burkitt's lymphoma.
Ji L; Arcinas M; Boxer LM
Mol Cell Biol; 1994 Dec; 14(12):7967-74. PubMed ID: 7969136
[TBL] [Abstract][Full Text] [Related]
13. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
14. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
15. Molecular biology of Burkitt's lymphoma.
Hecht JL; Aster JC
J Clin Oncol; 2000 Nov; 18(21):3707-21. PubMed ID: 11054444
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
17. Expression of P0- and P3-RNA from the normal and translocated c-myc allele in Burkitt's lymphoma cells.
Eick D; Polack A; Kofler E; Lenoir GM; Rickinson AB; Bornkamm GW
Oncogene; 1990 Sep; 5(9):1397-402. PubMed ID: 2216463
[TBL] [Abstract][Full Text] [Related]
18. The block to transcription elongation is promoter dependent in normal and Burkitt's lymphoma c-myc alleles.
Spencer CA; LeStrange RC; Novak U; Hayward WS; Groudine M
Genes Dev; 1990 Jan; 4(1):75-88. PubMed ID: 2307371
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
[TBL] [Abstract][Full Text] [Related]
20. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis.
Scholtysik R; Kreuz M; Klapper W; Burkhardt B; Feller AC; Hummel M; Loeffler M; Rosolowski M; Schwaenen C; Spang R; Stein H; Thorns C; Trümper L; Vater I; Wessendorf S; Zenz T; Siebert R; Küppers R;
Haematologica; 2010 Dec; 95(12):2047-55. PubMed ID: 20823134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
